Trials / Completed
CompletedNCT00871832
Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality
To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.
Conditions
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2009-03-30
- Last updated
- 2013-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00871832. Inclusion in this directory is not an endorsement.